8-KEarnings & ResultsSecurities & ListingExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 8, 2008)

Filed May 8, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 8, 2008, reporting its financial results for the first quarter ended March 31, 2008, and detailing an unregistered sale of equity securities to Novartis Pharma AG. The financial results announcement, attached as Exhibit 99.1, provides the company's operational and financial performance for the period. Investors should review this press release for detailed financial metrics and operational updates. A significant development reported is the full exercise of Novartis's right to purchase additional shares of Alnylam's common stock, pursuant to an existing Investor Rights Agreement. This transaction involved Novartis acquiring 213,888 unregistered shares at $25.29 per share, totaling approximately $5.4 million. This purchase increased Novartis's ownership stake in Alnylam from 12.9% to 13.4%, maintaining its desired ownership percentage and reinforcing a key strategic investor's commitment.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its financial results for the three months ended March 31, 2008.
  • 2Novartis Pharma AG exercised its right to purchase 213,888 shares of Alnylam's common stock.
  • 3The share purchase was made under the terms of the Investor Rights Agreement dated September 6, 2005.
  • 4The purchase price for the shares was $25.29 per share, totaling approximately $5.4 million.
  • 5Novartis's ownership increased from 12.9% to 13.4% of Alnylam's outstanding common stock.
  • 6The issuance of shares to Novartis was conducted under the exemption from registration provisions of Section 4(2) of the Securities Act.
  • 7The press release containing the financial results for Q1 2008 is attached as Exhibit 99.1 to the filing.

Frequently Asked Questions

This 8-K filing primarily served to announce Alnylam Pharmaceuticals' financial results for the first quarter ended March 31, 2008, and to report an unregistered sale of equity securities to Novartis Pharma AG.

Novartis's purchase of additional shares, amounting to approximately $5.4 million, demonstrates their continued strategic interest and commitment to Alnylam Pharmaceuticals. It allows Novartis to maintain its ownership percentage following Alnylam's issuance of shares related to stock option exercises and reinforces their position as a significant investor.

No, the 213,888 shares purchased by Novartis were unregistered. They were issued in reliance on the exemption from the registration provisions of the Securities Act, specifically under Section 4(2).

The detailed financial results are provided in the press release dated May 8, 2008, which is attached as Exhibit 99.1 to this Form 8-K filing. Investors should refer to this exhibit for specific financial performance data.